Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP… | Phase 3 | terminated | Feb 1, 2011 | Hoffmann-La Roche | The study was closed by the Sponsor according to the protocol-specified minimum post-treatment… | Other (stated, no rule matched) |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage… | Phase 1 | suspended | Nov 1, 2013 | National University Health System, Singapore | Suspended for an interim review of (CAR) CD19 research strategy for the treatment of CD19 positive… | Sponsor / business decision |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Jan 27, 2009 | Scripps Health | Unable to enroll | Enrollment / accrual |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | Phase 2 | terminated | May 15, 2017 | Prothena Biosciences Ltd. | NEOD001 program terminated due to lack of clinical benefit | Efficacy / futility |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Feb 27, 2019 | National Cancer Institute (NCI) | Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov | Other (stated, no rule matched) |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in… | Phase 2 | withdrawn | Jul 18, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | Phase 1 | terminated | Jun 10, 2011 | Merck Sharp & Dohme LLC | The study was terminated for business reasons. | Sponsor / business decision |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and… | Phase 4 | terminated | Jan 26, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With… | Phase 2 | terminated | Jun 15, 2009 | Sirtris, a GSK Company | Study terminated.24 subjects enrolled;provided adequate data for decision making. | Enrollment / accrual |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With… | Phase 1 / Phase 2 | terminated | Jul 27, 2011 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced… | Enrollment / accrual |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 20, 2017 | Eureka Therapeutics Inc. | Sponsor's Decision | Sponsor / business decision |
| NCT03168100 | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule… | Phase 2 | withdrawn | May 30, 2017 | University of Arkansas | No study population. No subjects enrolled. | Enrollment / accrual |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic… | Phase 1 | withdrawn | Nov 23, 2015 | Michael Choi | No participants enrolled | Enrollment / accrual |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | Phase 2 / Phase 3 | terminated | May 23, 2014 | Dr. med. Lars-Olof Muegge | Insufficient recruitment | Enrollment / accrual |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | Phase 1 | terminated | Apr 28, 2017 | Dana-Farber Cancer Institute | slow accrual | Enrollment / accrual |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | Phase 2 | terminated | Jul 14, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | MEDI-551 removed from oncology by pharmaceutical company due to change in research target. | Sponsor / business decision |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | Phase 1 / Phase 2 | terminated | Jul 4, 2013 | Adaptimmune | Sponsor Decision | Sponsor / business decision |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple… | Phase 1 / Phase 2 | terminated | Feb 25, 2011 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy…(BENEFIT) | Phase 2 | terminated | Dec 11, 2013 | Centre Leon Berard | Insufficient recruitment and unavailability of the treatment | Enrollment / accrual |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or… | Phase 3 | terminated | Nov 11, 2011 | AB Science | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and… | Phase 1 | withdrawn | Nov 21, 2017 | Gilead Sciences | The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the… | Other (stated, no rule matched) |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in… | Phase 2 | terminated | Jun 15, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | early stopping rule | Other (stated, no rule matched) |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT01235793 | The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed &…(DRBEAT) | Phase 2 | terminated | Nov 8, 2010 | Cedars-Sinai Medical Center | The clinical trial was terminated due to poor enrollment | Enrollment / accrual |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System… | Phase 2 | withdrawn | Apr 19, 2017 | PIQUR Therapeutics AG | Withdrawn | Other (stated, no rule matched) |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT00038883 | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | N/A | terminated | Mar 3, 2015 | University of Arizona | PI left the department; protocol transfer did not take place. | Investigator |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple…(PrE1003) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | PrECOG, LLC. | Slow enrollment | Enrollment / accrual |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Aug 31, 2012 | NYU Langone Health | PI left the institution | Investigator |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel…(rev/abraxane) | Phase 1 / Phase 2 | terminated | Mar 3, 2014 | NYU Langone Health | PI left the institution | Investigator |
| NCT02055924 | Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas(BIBLOS) | Phase 1 | terminated | Feb 5, 2014 | The Lymphoma Academic Research Organisation | ANSM decision due to veino occlusive disease (security alert) | Other (stated, no rule matched) |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron(VRCD) | Phase 2 | terminated | Dec 20, 2006 | Oncology Specialists, S.C. | not stated | Not stated |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed… | Phase 1 / Phase 2 | terminated | Aug 27, 2012 | University Health Network, Toronto | The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015. | Drug supply |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed… | Phase 1 | terminated | Jun 4, 2015 | AbbVie | No Go decision for ABBV-838 | Other (stated, no rule matched) |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | Phase 3 | terminated | Jul 3, 2015 | Boston Medical Center | Enrollment held for toxicity evaluation; then closed due to competing trial | Safety / toxicity |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With… | Phase 2 | terminated | Jun 11, 2009 | Weill Medical College of Cornell University | The study was terminated early due to lack of accrual. | Enrollment / accrual |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated… | Phase 1 / Phase 2 | withdrawn | Aug 29, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell… | Phase 2 | terminated | Feb 19, 2009 | Lymphoma Study Association | Inefficiency of treatment | Other (stated, no rule matched) |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | Phase 1 | terminated | Jan 8, 2014 | Weill Medical College of Cornell University | The company providing one of the study drugs withdrew its support due to low enrollment. Therefore,… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 12, 2019source: clinicaltrials